Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.45 |
| ▸ | ERN1 | O75460 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TPI1 | P60174 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13743260 | 0.72 | KIF11 (0.61) | PTGES2KIF11ALOX5APFEN1 | |
| SCHEMBL6732618 | 0.72 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL6722914 | 0.72 | PTGS2 (0.46) | PTGS2PTGS1KIF11ALOX5APFEN1 | |
| SCHEMBL1015776 | 0.70 | ERN1 (0.45) | ERN1PARP1TPI1PARP2TOP2A | |
| SCHEMBL23832427 | 0.70 | PTGES2 (0.63) | PTGES2CA2 | |
| SCHEMBL6723595 | 0.70 | PTGS2 (0.41) | PTGS2PTGS1KIF11ALOX5APFEN1 | |
| SCHEMBL789994 | 0.69 | PTGS1 (0.48) | PTGES2PTGS2PTGS1CA2 | |
| SCHEMBL29556118 | 0.69 | PTGS1 (0.48) | PTGES2PTGS2PTGS1CA2 | |
| SCHEMBL13742993 | 0.68 | KIF11 (0.56) | PTGS2PTGS1KIF11CA2 | |
| Iodide SCHEMBL28547721 | 0.67 | PTGS1 (0.47) | PTGES2PTGS2PTGS1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | PTGES2 547/4885PTGS2 558/4885PTGS1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.